Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

River blindness vaccine set for cattle trials
The vaccine is being developed by biotechnology company Vaxine Pty.

Vaccine uses unique sugar-based adjuvant

Scientists in Australia are developing a vaccine that could prevent millions of cases of river blindness.

According to The Lead South Australia, the vaccine is being developed by biotechnology company Vaxine Pty and is set for trials in 2017.

Vaxine scientific director Nikolai Petrovsky explained that the vaccine uses a two-pronged approach to effectively prevent the disease.


“First we’re looking to vaccinate the cattle, which are a breeding ground for the parasite,” he said. 
“Then, the other side of this is to immunise the children so if they come in contact with the parasite it blocks the infection.


“Our technology is a bit like melding a turbocharger to the engine and in this case makes the vaccine dramatically more powerful.”

According to the World Health Organisation, river blindness affects some 17 million people globally. Ninety per cent of these cases occur in west and central Africa.


Caused by the parasitic worm Onchocerca volvulus, river blindness is spread to humans and cattle by blackflies that breed in rivers. Symptoms of the disease include severe itching, disfigurative skin conditions and visual impairment - including permanent blindness.

Professor Petrovsky said the new vaccine uses a unique sugar-based adjuvant, which is safer than existing methods.

“We offer a new alternative that is not only potentially safer because it is a sugar instead of a metal/salt with high toxicity,” he told The Lead. 

“Our adjuvant also works for a lot of vaccines that wouldn’t work with aluminium. The ones that tried to create an onchocerciasis vaccine didn’t take but ours actually works.”

The vaccine was developed in association with Thomas Jefferson University and the New York Blood Centre in the United States.

The team have received a grant from the US government and hope to begin tests for the cattle trial in the coming weeks.

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
Lords Committee opens Pet Parasite Medication inquiry

The House of Lords Environment and Climate Change Committee will launch its inquiry into Pet Parasite Medication (PPM) on Wednesday (3 June).

Focusing on treatments containing fipronil and imidacloprid, the inquiry will seek to understand distribution pathways and the impacts of PPM use and non-use on biodiversity and human health. It will also cover current regulation, monitoring, and the potential implications for pets and their owners.

The committee will hear evidence from environmental non-governmental organisations and research institutes. The public can follow the proceedings live on Parliament TV or in person in the Palace of Westminster.